## Pheruza Tarapore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7617686/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Perfluoroalkyl Chemicals and Male Reproductive Health: Do PFOA and PFOS Increase Risk for Male Infertility?. International Journal of Environmental Research and Public Health, 2021, 18, 3794.	2.6	63
2	PFOA Exposure Prior to Hepatocyte Differentiation Leads to Gene Expression Changes Implicated in Non-Alcoholic Fatty Liver Disease. Journal of the Endocrine Society, 2021, 5, A490-A491.	0.2	0
3	Three-Generation Study of Male Rats Gestationally Exposed to High Butterfat and Bisphenol A: Impaired Spermatogenesis, Penetrance with Reduced Severity. Nutrients, 2021, 13, 3636.	4.1	5
4	Bisphenol A and its analogues disrupt centrosome cycle and microtubule dynamics in prostate cancer. Endocrine-Related Cancer, 2017, 24, 83-96.	3.1	44
5	Ca <sup>2+</sup> Selective Host Rotaxane Is Highly Toxic Against Prostate Cancer Cells. ACS Medicinal Chemistry Letters, 2017, 8, 163-167.	2.8	11
6	Calcium phosphate-polymer hybrid nanoparticles for enhanced triple negative breast cancer treatment via co-delivery of paclitaxel and miR-221/222 inhibitors. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 403-410.	3.3	67
7	High butter-fat diet and bisphenol A additively impair male rat spermatogenesis. Reproductive Toxicology, 2017, 68, 191-199.	2.9	18
8	Abstract 2537: MicroRNA targeting anti-apoptotic and G2/M pathways as therapeutic targets for castration resistant prostate cancer. , 2017, , .		0
9	Data on spermatogenesis in rat males gestationally exposed to bisphenol A and high fat diets. Data in Brief, 2016, 9, 812-817.	1.0	4
10	Cancer and Developmental Origins of Health and Disease—Epigenetic Reprogramming as a Mediator. , 2016, , 315-336.		4
11	Exposure to Bisphenol A Correlates with Early-Onset Prostate Cancer and Promotes Centrosome Amplification and Anchorage-Independent Growth In Vitro. PLoS ONE, 2014, 9, e90332.	2.5	92
12	Crown Ether Host-Rotaxanes as Cytotoxic Agents. ACS Medicinal Chemistry Letters, 2013, 4, 27-31.	2.8	10
13	Estrogen Receptor $\hat{I}^2$ Isoform 5 Confers Sensitivity of Breast Cancer Cell Lines to Chemotherapeutic Agent-Induced Apoptosis through Interaction with Bcl2L12. Neoplasia, 2013, 15, 1262-IN15.	5.3	27
14	Biology and Clinical Relevance of Estrogen Receptors in Prostate Cancer. , 2013, , 383-419.		0
15	Estrogen Receptor β (ERβ1) Transactivation Is Differentially Modulated by the Transcriptional Coregulator Tip60 in a cis-Acting Element-dependent Manner. Journal of Biological Chemistry, 2013, 288, 25038-25052.	3.4	12
16	Environmental Epigenetics and Its Implication on Disease Risk and Health Outcomes. ILAR Journal, 2012, 53, 289-305.	1.8	201
17	Estrogen receptor-beta and breast cancer: Translating biology into clinical practice. Steroids, 2012, 77, 727-737.	1.8	57
18	Analysis of centrosome localization of BRCA1 and its activity in suppressing centrosomal aster formation. Cell Cycle, 2012, 11, 2931-2946.	2.6	24

#	Article	IF	CITATIONS
19	Site-Specific S-Nitrosylation of Integrin α6 Increases the Extent of Prostate Cancer Cell Migration by Enhancing Integrin β1 Association and Weakening Adherence to Laminin-1. Biochemistry, 2012, 51, 9689-9697.	2.5	19
20	Application of Phi29 Motor pRNA for Targeted Therapeutic Delivery of siRNA Silencing Metallothionein-IIA and Survivin in Ovarian Cancers. Molecular Therapy, 2011, 19, 386-394.	8.2	56
21	Direct evidence for the role of centrosomally localized p53 in the regulation of centrosome duplication. Oncogene, 2007, 26, 2939-2944.	5.9	86
22	Thr199phosphorylation targets nucleophosmin to nuclear speckles and represses pre-mRNA processing. FEBS Letters, 2006, 580, 399-409.	2.8	52
23	Liver-Specific pRB Loss Results in Ectopic Cell Cycle Entry and Aberrant Ploidy. Cancer Research, 2005, 65, 4568-4577.	0.9	94
24	Characterization of centrosomal association of nucleophosmin/B23 linked to Crm1 activity. FEBS Letters, 2005, 579, 6621-6634.	2.8	51
25	A Mammalian In Vitro Centriole Duplication System: Evidence for Involvement of CDK2/Cyclin E and Nucleophosmin/B23 in Centrosome Duplication. Cell Cycle, 2002, 1, 72-78.	2.6	50
26	Loss of p53 and centrosome hyperamplification. Oncogene, 2002, 21, 6234-6240.	5.9	169
27	A mammalian in vitro centriole duplication system: evidence for involvement of CDK2/cyclin E and nucleophosmin/B23 in centrosome duplication. Cell Cycle, 2002, 1, 75-81.	2.6	27
28	Direct regulation of the centrosome duplication cycle by the p53-p21Waf1/Cip1 pathway. Oncogene, 2001, 20, 3173-3184.	5.9	138
29	Difference in the centrosome duplication regulatory activity among p53 †hot spot' mutants: potential role of Ser 315 phosphorylation-dependent centrosome binding of p53. Oncogene, 2001, 20, 6851-6863.	5.9	48
30	Specific Phosphorylation of Nucleophosmin on Thr199 by Cyclin- dependent Kinase 2-Cyclin E and Its Role in Centrosome Duplication. Journal of Biological Chemistry, 2001, 276, 21529-21537.	3.4	192
31	Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression. Oncogene, 2000, 19, 1635-1646.	5.9	134
32	Nucleophosmin/B23 Is a Target of CDK2/Cyclin E in Centrosome Duplication. Cell, 2000, 103, 127-140.	28.9	628
33	p53 Mutation and Mitotic Infidelity. Cancer Investigation, 2000, 18, 148-155.	1.3	47
34	Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene, 1999, 18, 1935-1944.	5.9	261
35	DNA Binding and Transcriptional Activation by the Ski Oncoprotein Mediated by Interaction with NFI. Nucleic Acids Research, 1997, 25, 3895-3903.	14.5	44